Therapeutic efficacy against Mycobacterium tuberculosis using ID93 and liposomal adjuvant formulations.
Therapeutic efficacy against Mycobacterium tuberculosis using ID93 and liposomal adjuvant formulations.
复制标题
DOI：
10.3389/fmicb.2022.935444
复制
发表时间：
2022
影响因子：
5.2
通讯作者：
中科院分区：
文献类型：
--
作者：
根据世界卫生组织（WHO）的数据，结核分枝杆菌（M.tb）在2020年已导致全球约130万人死亡。因此，需要更有效的治疗来预防结核杆菌的传播。虽然卡介苗（BCG），一种针对结核分枝杆菌的预防性疫苗，已经存在，但其他疫苗正在开发中，可能有助于提高BCG的不完全保护。这包括ID 93 + GLA-SE，这是一种正在2期临床试验中进行测试的佐剂蛋白疫苗。本研究的目的是在治疗性疫苗的背景下测试具有ID 93的新的基于脂质的佐剂制剂，我们假设其将作为药物治疗的辅助，并提供比单独药物治疗更好的结果，例如存活率。另一种含佐剂的重组蛋白疫苗M72 + AS 01 E（GlaxoSmithKline Biologicals）最近的成功，在3年后提供了约50%的抗结核肺部疾病的疗效，为新的和可能更有效的疫苗铺平了道路。我们表明，基于选定的标准，包括生存率、辅助性T细胞因子1反应和肺部驻留记忆T细胞，GLA与QS-21（GLA-LSQ）联合ID 93的脂质体制剂提供了比单独药物治疗更强的保护作用。
Mycobacterium tuberculosis (M.tb) has led to approximately 1.3 million deaths globally in 2020 according to the World Health Organization (WHO). More effective treatments are therefore required to prevent the transmission of M.tb. Although Bacille Calmette–Guérin (BCG), a prophylactic vaccine against M.tb, already exists, other vaccines are being developed that could help boost BCG’s noted incomplete protection. This includes ID93 + GLA-SE, an adjuvanted protein vaccine which is being tested in Phase 2 clinical trials. The aim of this study was to test new lipid-based adjuvant formulations with ID93 in the context of a therapeutic vaccine, which we hypothesize would act as an adjunct to drug treatment and provide better outcomes, such as survival, than drug treatment alone. The recent success of another adjuvanted recombinant protein vaccine, M72 + AS01E (GlaxoSmithKline Biologicals), which after 3 years provided approximately 50% efficacy against TB pulmonary disease, is paving the way for new and potentially more effective vaccines. We show that based on selected criteria, including survival, T helper 1 cytokine responses, and resident memory T cells in the lung, that a liposomal formulation of GLA with QS-21 (GLA-LSQ) combined with ID93 provided enhanced protection over drug treatment alone.
登录
查看更多内容
影响因子：
7.3
作者：
Larsen SE;Williams BD;Rais M;Coler RN;Baldwin SL
通讯作者：
Baldwin SL
影响因子：
24.8
作者：
Kauffman KD;Sakai S;Lora NE;Namasivayam S;Baker PJ;Kamenyeva O;Foreman TW;Nelson CE;Oliveira-de-Souza D;Vinhaes CL;Yaniv Z;Lindestam Arleham CS;Sette A;Freeman GJ;Moore R;NIAID/DIR Tuberculosis Imaging Program;Sher A;Mayer-Barber KD;Andrade BB;Kabat J;Via LE;Barber DL
通讯作者：
Barber DL
影响因子：
6.4
作者：
Coler, Rhea N.;Bertholet, Sylvie;Reed, Steven G.
通讯作者：
Reed, Steven G.
影响因子：
11.8
作者：
Nahid, Payam;Dorman, Susan E.;Vernon, Andrew
通讯作者：
Vernon, Andrew
影响因子：
17.1
作者：
Bertholet S;Ireton GC;Ordway DJ;Windish HP;Pine SO;Kahn M;Phan T;Orme IM;Vedvick TS;Baldwin SL;Coler RN;Reed SG
通讯作者：
Reed SG